Mitsubishi UFJ Asset Management (UK)’s Vertex Pharmaceuticals VRTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$993K Sell
2,000
-2,000
-50% -$886K 0.46% 67
2026
Q1
$1.79M Buy
+4,000
New +$1.87M 0.92% 37
2025
Q4
Sell
-2,200
Closed -$862K 112
2025
Q3
$862K Buy
+2,200
New +$919K 0.42% 68
2025
Q2
Sell
-1,000
Closed -$485K 118
2025
Q1
$485K Sell
1,000
-1,500
-60% -$699K 0.26% 84
2024
Q4
$1.01M Buy
+2,500
New +$1.16M 0.44% 58

Other funds holding VRTX

Mitsubishi UFJ Asset Management (UK)'s VRTX Position: Q2 2026 in Review

Mitsubishi UFJ Asset Management (UK) reduced its Vertex Pharmaceuticals (VRTX) stake by 50% in Q2 2026, selling an estimated $886K and leaving 2,000 shares worth $993K. The position accounts for 0.46% of the portfolio, ranked #67.

Mitsubishi UFJ Asset Management (UK) first reported a position in VRTX in Q4 2024 and has held it in 5 quarters since. The position peaked at $1.79M in Q1 2026. 578 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Mitsubishi UFJ Asset Management (UK) held 2,000 shares of Vertex Pharmaceuticals worth $993K as of Q2 2026.
  • Mitsubishi UFJ Asset Management (UK) sold 2,000 Vertex Pharmaceuticals shares in Q2 2026, an estimated $886K.
  • Vertex Pharmaceuticals made up 0.46% of Mitsubishi UFJ Asset Management (UK)'s portfolio in Q2 2026, its #67 holding.
  • Mitsubishi UFJ Asset Management (UK) first reported a position in Vertex Pharmaceuticals in Q4 2024 and has held it in 5 quarters since.
  • Mitsubishi UFJ Asset Management (UK)'s Vertex Pharmaceuticals position peaked at $1.79M in Q1 2026.
  • 578 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Mitsubishi UFJ Asset Management (UK)'s 13F filing for Q2 2026, filed 28 Jul 2026.